Answers are grounded in this paper and cite their sources.
Background: Numerous studies have proven the survival benefit attained with the use of adjuvant hormonal therapy in breast cancer (BC) patients with hormone receptor-positive disease yet a percentage of women fail to comply with this effective therapy. Objectives: We investigated the rate of adherence and discontinuation among Egyptian women with BC who were prescribed adjuvant oral hormonal therapy. Methods: A cross-sectional, questionnaire-based study was performed at two Egyptian centers and recruited women with hormonal receptor-positive BC who received at least one adjuvant oral hormonal therapy prescription within 12 months from diagnosis. Results: A total of 229 patients were included with a mean age of 54.2 ±11.1 years and 55.9% were from a governmental University hospital. Patients had at least a university degree in 59.4% of the cases. Less than half of the patients had stage II (45.4%) BC and 71.2% had received adjuvant chemotherapy. The most commonly prescribed hormonal therapy was aromatase inhibitors (48.5%). Ovarian function suppression was used in 15.3% of our cohort. Governmental funding (77.7%) was the main provider. A discontinuation of 10.9% and an adherence of 64.2% to adjuvant hormonal agents were recorded. Bothersome adverse events were the main reason for discontinuation (92%), whilst forgetfulness (30%), toxicity (17.5%) and COVID-19infection (12.5%) were listed as the main causes of non-adherence by the participants in the study. Conclusion: Egyptian breast cancer patients displayed adherence and discontinuation rates similar to those reported worldwide. Future interventional strategies are encouraged to improve endocrinal therapy adherence and correlate it to outcome.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: